All Stories

Marea rises toward phase 2b after showing antibody cuts remnant cholesterol

Marea Therapeutics has linked its lead candidate to a 53% placebo-adjusted mean reduction in remnant cholesterol, positioning the biotech to start a phase 2b trial imminently.

May 8, 2025 - 23:17
 0
Marea rises toward phase 2b after showing antibody cuts remnant cholesterol
Marea Therapeutics has linked its lead candidate to a 53% placebo-adjusted mean reduction in remnant cholesterol, positioning the biotech to start a phase 2b trial imminently.
Read More

Tags:

Previous Article

CRISPR Therapeutics sees 80% fall in LDL, triglycerides after in vivo liver editing

Next Article

Neurocrine hands back 2 CNS gene therapy programs to Voyager

Related Posts

Biohaven, after setbacks, sees shares jump with Oberland Capital funding agreement worth up to $600M

Biohaven, after setbacks, sees shares jump with Oberlan...

Apr 28, 2025  0

RallyBio cuts deeper, laying off 40% of workforce after halting work on lead drug

RallyBio cuts deeper, laying off 40% of workforce after...

May 8, 2025  0

Roche looks to expand and upgrade US research centers as part of $50B investment strategy in the country

Roche looks to expand and upgrade US research centers a...

Apr 22, 2025  0